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Abstract
Background: Focal nodular hyperplasia (FNH) is a common benign disease of the liver with no recog-
nized potential for malignant transformation. The term describes an entity of lobular proliferation of
normally differentiated hepatocytes, frequently around a central fibrous scar. Two key issues influence
surgical decision making in FNH: diagnostic certainty, and symptomatic assessment.
Methods: A systematic review of studies reporting hepatic resections of FNH was performed. Indica-
tions and outcomes in adult populations were examined with a focus on diagnostic workup, patient
selection and operative mortality and morbidity.
Results: Diagnostic modalities in the majority of studies involved ultrasound and computed tomography.
Fewer than half employed magnetic resonance imaging (MRI). In instances in which MRI was not
available, diagnostic accuracy was inferior.
Conclusions: Percutaneous biopsy should be avoided to prevent the risk for tumour seeding. Patients
presenting with asymptomatic definitive FNH can be safely managed conservatively. In symptomatic
patients surgical resection is a safe and effective treatment for which acceptable rates of morbidity (14%)
and zero mortality are reported. However, evidence of symptom resolution is reported with conservative
strategies. Diagnostic uncertainty remains the principal valid indication for FNH resection, but only in
patients in whom contrast-enhanced MRI forms part of preoperative assessment.
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Introduction
Focal nodular hyperplasia (FNH) is a common benign disease of
the liver. Its incidence in females is reported to be eight times
higher than in males and is weakly associated with reproductive
age and use of oral contraceptives. The term describes an entity of
lobular proliferation of normally differentiated hepatocytes, fre-
quently around a central fibrovascular scar.1 The natural history of
FNH has been well studied and there is a sound evidence base for
its benign classification. No instances of confirmed malignant
transformation of FNH are reported in the literature.2
The profile of the typical FNH patient has changed as a result of
the modern widespread availability and application of cross-
sectional imaging. Previously, a significant proportion of patients
diagnosed with FNH presented with vague symptoms of abdomi-
nal pain or discomfort. Such patients then proceeded to imaging
and diagnosis. Today, the converse is true and the prevalent sce-
nario concerns the incidental detection of liver lesions through
high-resolution imaging performed for unrelated clinical reasons.
As a result there has been broad international recognition of a
substantial increase in the number of referrals for the characteri-
zation and subsequent management of suspected FNH.
There exists considerable controversy with respect to the abso-
lute indications and contraindications for surgery in benign liver
disease,3 and the available literature is unclear regarding the sur-
gical management of FNH. The management spectrum ranges
from simple observation to major hepatic resection, with two key
issues influencing clinical decision making. The first is diagnostic
certainty and the second symptomatic assessment. The lack of
malignant potential in FNH means that when relative certainty is
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achieved, the asymptomatic patient might be safely managed con-
servatively. However, in patients in whom indeterminate features
exist, the differential diagnosis includes more concerning pathol-
ogies, such as hepatic adenoma (HA) or fibrolamellar hepatocel-
lular carcinoma (FHCC). For such lesions resection is justified to
prevent the development or under-treatment of malignancy. In
symptomatic patients in whom FNH lesions are plausibly deemed
to be causal, resection has been performed and reported for
palliation.
This systematic review focuses on studies that report outcomes
of FNH resections and give details of the preoperative diagnostic
and patient selection modalities employed. Outcomes assessed are
the accuracy of preoperative diagnostic investigations, stated indi-
cations for surgery, operative procedure, mortality, morbidity and
patient satisfaction. Thus the indications for conservative versus
surgical management of suspected FNH might be more clearly
understood.
Materials and methods
Literature search strategy
A systematic review of the literature was undertaken according to
the principles of the PRISMA (preferred reporting items for sys-
tematic reviews and meta-analyses) guidelines.4 No randomized
studies precluding the application of relevant PRISMA items were
identified.
An electronic search of the PubMed and MEDLINE databases
was performed for the period 2001 to 2012 inclusive using the
MeSH (medical subject headings) terms: ‘focal nodular hyperpla-
sia’; ‘liver tumours’; ‘liver resection’, and ‘hepatectomy’. The search
was limited to English-language publications and studies on adult
human subjects. All titles and abstracts were reviewed, and appro-
priate papers assessed for inclusion. The reference sections of all
papers initially included were also assessed to ensure the identifi-
cation of all relevant studies.
Inclusion and exclusion criteria
Studies were included if they described outcomes following
hepatic resection in patients with FNH. Data collated included
preoperative diagnostic methods used, indications for surgery,
magnitude of hepatic resection and postoperative outcomes. The
minimal dataset eligible for inclusion was required to refer to
patients with FNH treated with surgery and to present diagnostic
modality and patient outcome data. Series of hepatic resections
for general benign disease were required to present specific FNH
subgroup data. All series satisfying these criteria were included
regardless of the size of the study population. Case reports, edito-
rials, unpublished data from conference abstracts and review arti-
cles were excluded. The characteristics of excluded studies are
shown in Fig. 1.
Results
Characteristics of included studies
Of the 14 studies reviewed, three focused exclusively on patients
with FNH.5–7 Nine further studies can be described as case series of
hepatic resections performed for benign disease, including
FNH.8–16 The remaining two studies reported on resections of
both benign and malignant liver lesions.17,18 In total, the 14 studies
involved 885 patients submitted to surgery for benign liver lesions,
37% (n = 331) of whom had a proven histological diagnosis of
FNH (Table 1).
Diagnostic modalities
Seven studies provided details of the diagnostic modalities
employed preoperatively in a total of 195 FNH patients.5–7,9,11,12,18
The reference-standard method of diagnosis of FNH is histologi-
cal analysis.
Lesional biopsy
Only two studies included data on the use of biopsy in the context
of the management of presumed FNH. Descottes and colleagues11
reported preoperative liver investigations performed in 87
patients with benign lesions, 48 (55%) of whom were ultimately
histologically diagnosed as having FNH. Within the subgroup of
patients with FNH, 23% (n = 11) subsequently underwent either
percutaneous (n = 3) or laparoscopic (n = 8) tumour biopsy.
Biopsy-derived histological diagnoses were poorly correlated with
resection specimen histology. Six (55%) true positive results were
seen. The remaining findings included four false positive results
Potentially relevant studies identified 
after duplicates removed 
Screened by title and abstract for 
retrieval 
n = 120
Studies excluded n = 85
Case reports n = 20
Abstracts n = 15
Review articles n = 21
Non-English n = 7
Not relevant n = 22 
Studies retrieved for more detailed 
full-text evaluation n = 35
Studies excluded n = 21
Paediatric series n = 4
Review articles n = 3
Failed to meet minimum dataset 
requirements n = 14
Studies included in review n = 14
Studies identified through 
database searching
n = 120
Studies identified through 
other sources
n =  6
Figure 1 Flow diagram demonstrating search criteria and subse-
quent inclusion of relevant studies
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referring to the misdiagnosis of three adenomas and one hepato-
cellular carcinoma (HCC) and one inconclusive result.
Bonney and colleagues5 reported a series of 52 patients with
FNH who were either treated operatively (n = 15, 29%) or
managed conservatively (n = 37, 71%). Seven patients in the con-
servatively managed group were diagnosed with FNH following
histopathological analysis of percutaneous biopsies. Of the 15
patients with FNH managed with resection, five patients under-
went preoperative percutaneous biopsy. A definitive diagnosis of
FNH was achieved in only two (13%) patients.
Use and accuracy of preoperative imaging for
FNH diagnosis
Ultrasound
Shen and colleagues7 reported the use of contrast-enhanced ultra-
sound (US) in 79 of 86 (92%) patients undergoing resection for
lesions that were histologically diagnosed as FNH. Ultrasound
achieved an accurate diagnosis of FNH in 33% (n = 26) of
patients. Of the remaining 53 patients, 28 had an equivocal US
diagnosis and 25 were over-diagnosed as having malignant
lesions.
Table 1 Published studies of patients with focal nodular hyperplasia (FNH) treated with hepatic resection
Study Patients,
n
Benign
resections,
n
FNH
resections,
n
Overall
morbidity,
n (%)
FNH-
specific
morbidity,
n (%)
Major
resectiona,
n (%)
Minor
resectiona,
n (%)
Resection
indication:
symptomatic,
n (%)
Resection
indication:
diagnostic
uncertainty,
n (%)
Follow-up,
months,
median
(range)
Charny et al.
(2001)8 (USA)
155 68 18 14 (21%) N/A 8 (44%) 10 (55%) 8 (44%) 13 (72%) 16
Descottes et al.
(2003)11
(France)
87 87 48 4 (5%) N/A 0b 51 (100%)b 23 (45%)b 28 (55%)b 10 (2–72)
Clarke et al.
(2004)9 (UK)
49 49 12 15 (31%) N/A N/A N/A 10 (83%) 2 (17%) N/A
Liu et al.
(2004)18 (China)
107 45 17 7 (16%) N/A N/A N/A 0 17 (100%) N/A
Fioole et al.
(2005)12
(Netherlands)
28 28 6 8 (29%) N/A 2 (33%) 4 (67%) 1 (17%) 5 (83%) N/A
Skalicky et al.
(2005)16 (Czech
Republic)
43 43 14 3 (7%) N/A 4 (29%) 10 (71%) N/A N/A N/A
Hsee et al.
(2005)6 (New
Zealand)
8 8 8 4 (50%) 4 (50%) 2 (25%) 6 (75%) 7 (88%) 1 (12%) N/A
Shen et al.
(2007)7 (China)
86 86 86 6 (7%) 6 (7%) 17 (20%) 69 (80%) N/A N/A 45 (6–60)
Bonney et al.
(2007)5 (UK)
52 15 15 3 (20%) 3 (20%) 6 (40%) 9 (60%) 8 (53%) 7 (47%) 23 (3–84)
Petri et al.
(2008)15
(Hungary)
132 112 21 31 (28%) 7 (33%) 4 (19%)c 17 (81%) N/A N/A N/A
Lordan et al.
(2009)14 (UK)
79 79 16 7 (9%) N/A 7 (44%) 9 (56%) 6 (38%) 12 (75%) N/A
Erdogan et al.
(2009)17
(Netherlands)
70 70 12 15 (21%) N/A N/A N/A 10 (83%) 2 (17%) N/A
Dardenne et al.
(2010)10
(Belgium)
132 49 13 7 (14%) 0 0 13 (100%) 3 (23%) 10 (77%) 115 (2–233)
Kamphues et al.
(2011)13
(Germany)
146 146 45 25 (17%) N/A N/A N/A N/A N/A 50 (3–95)
aMajor resection: more than three Couinaud segments; minor resection: up to three Couinaud segments.
b48 patients with FNH were grouped with three patients in whom histology showed hamartoma.
cIncludes one liver transplant.
N/A, not available.
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Bonney and colleagues5 performed an US examination in 27
(52%) patients and achieved an unequivocal diagnosis in eight
(30%) of them.Descottes and colleagues11 reported using US in 85
(98%) patients, but did not present data on its accuracy. The small
FNH series presented by Clarke et al.9 (n = 12), Fioole et al.12 (n =
6) and Liu et al.18 (n = 17) all employed preoperative US routinely,
but did not present accuracy data. In the latter study,18 the patient
cohort was heterogeneous with respect to histological diagnosis
and details of investigations by histological subgroup were not
provided. Similarly, accuracy data were not available.
Computed tomography
Shen and colleagues7 reported the use of multiphase computed
tomography (CT) in 67% (n = 58) of their patients and described
it as diagnostic in 60% (n = 35). Bonney and colleagues5 per-
formed CT in 34 (65%) patients, in 24 (70%) of whom the
method achieved a diagnosis of FNH. Descottes and colleagues11
reported using CT in 74 (85%) patients but did not present infor-
mation on its diagnostic accuracy. Computed tomography (with
US) was used routinely in all FNH patients reported by Clarke
et al.,9 Fioole et al.12 and Liu et al.18 However, as with their US data,
these studies did not present information on accuracy.
Magnetic resonance imaging
Magnetic resonance imaging (MRI)wasemployedsparinglybyShen
and colleagues7 (n = 31, 36%) but produced an accurate diagnosis of
FNH in 77% (n = 24) of patients. Twenty-two patients in this study
underwent both preoperative CT and MRI. This combined
approach yielded an accurate FNH diagnosis in 20 (91%) cases.7
Bonney et al.5 used MRI in 46 (88%) patients. Their findings
with respect to diagnostic accuracy were broadly similar to those
of Shen and colleagues.7 Bonney et al.5 reported that MRI
achieved a definitive diagnosis of FNH in 40 (87%) patients. An
interesting feature of the study by Bonney et al.5 is its inclusion of
a majority of conservatively managed patients (n = 37/52, 71%).
This may have resulted from the availability of MRI and hence a
potential reduction in the number of resections performed for
uncertain diagnoses. However, conclusions on diagnostic accu-
racy are limited as subsequent histological confirmation of the
diagnosis does not apply in patients managed conservatively. In
six of the 15 patients resected (40%), a definitive preoperative
diagnosis of FNH was made using imaging alone. These patients
were resected for symptoms. In the remaining seven (47%)
patients, preoperative investigations were inconclusive. The
remaining two patients were diagnosed following lesional biopsy.
Descottes and colleagues11 reported the use of MRI in 44 (51%)
patients. Clarke et al. did not have access toMRI during the assess-
ment of 12 FNH cases.9 Liu et al. did not state whether preopera-
tive liver MRI was employed in 17 FNH patients.18 Similarly,
Fioole and colleagues did not performMRI or preoperative biopsy
in any of the six cases of FNH reported.12
The studies by Charny et al.8 and Dardenne et al.10 failed to
provide complete information on preoperative diagnostic meth-
odology. However, Charny et al. did report that a preoperative
diagnosis was achieved in seven (39%) of the 18 patients who
proceeded to resection for FNH.8 Dardenne et al. discussed the
characteristic features of FNH used for diagnosis on CT and MRI
cross-sectional imaging and reported a preoperative diagnosis rate
of 48% (n = 29) using these modalities.10
Summary
Across the seven studies analysed herein,5–7,9,11,12,18 preoperative US
was performed in 84% (n = 163), CT in 76% (n = 149) and MRI
in 48% (n = 93) of patients. The remaining patients (n = 19, 10%)
underwent both imaging and either percutaneous or laparoscopic
lesional biopsy. None of the studies reviewed provided detailed
information on specific imaging protocols or the contrast agents
used in MRI or CT.
Many clinicians believe that, using the modalities described
above, an FNH diagnosis can be made with a high level of confi-
dence in the majority of patients without requiring resection.
However, as is apparent here, the literature-based support for such
an assertion is sparse.
Indications for surgery
Nine studies reported data regarding indications for surgery for
FNH.5,6,8–10,12,14,17,18 Although the semantics of the indications
described vary among studies, all can be categorized as relating to
either patient symptoms or diagnostic uncertainty and suspicion
of cancer.
Charny and co-workers8 performed 18 hepatic resections for
FNH. In 61% (n = 11) of these cases, the indication for surgery
referred to diagnostic uncertainty on preoperative imaging,
although a further two (11%) patients were resected following an
increase in lesion size during follow-up.8 Presumably diagnostic
uncertainty represented the rationale for surgery in these cases
also. The remaining reported indication referred to symptomatic
lesions (n = 8, 44%). Three patients had dual indications for
resection (i.e. diagnostic uncertainty and symptoms). The nature
of the symptoms experienced was not reported.8
Descottes and colleagues11 reported a series of 51 hepatic resec-
tions in 48 patients with FNH and three patients with hamartoma.
Indications for resection were symptoms in 23 (45%) patients and
diagnostic uncertainty or atypical radiological appearance in 18
(35%). In 10 (20%) patients, resection was performed for hepatic
lesions detected during laparoscopic procedures performed for
separate indications. It is presumed that these lesions were inci-
dental findings as no information regarding preoperative imaging
was reported.
Clarke and co-workers9 published a series of 49 cases of hepatic
resection for benign non-cystic lesions. Twelve patients had a
postoperative histological diagnosis of FNH. The authors recom-
mended conservative management for asymptomatic patients
with a radiological diagnosis of FNH.9 Patients with symptomatic
lesions, diagnostic uncertainty or enlarging lesions were offered
hepatic resection. Symptomatic FNH was the stated indication for
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resection in 10 (83%) of the 12 patients. No clear definition of
‘symptomatic FNH’ was described in this study. In two (17%)
FNH cases, preoperative investigations had suggested a diagnosis
of liver cell adenoma. Resection had subsequently been performed
and provided a final histological diagnosis of FNH.9
Bonney and co-workers5 presented data for 15 patients with
FNH submitted to hepatic resection between 1997 and 2006. In
eight (53%) patients abdominal pain was the stated indication for
surgery. However, the majority (n = 13, 87%) of the FNH patients
reported moderate or severe abdominal pain. The indication for
resection in the remaining seven patients was diagnostic uncer-
tainty on preoperative imaging or suspicion of malignancy on
biopsy (n = 3, 43%).5
Within these nine studies,5,6,8–10,12,14,17,18 97 (58%) patients
underwent hepatic resection without a definitive preoperative
diagnosis of FNH; the primary indication for surgery in these
patients was therefore diagnostic uncertainty. Resection was per-
formed in 76 (43%) patients to palliate abdominal symptoms
attributable to a hepatic lesion. The data presented across all of
these studies did not allow for assessment of the aetiology of pain,
which may derive from mass effect, impingement on other struc-
tures or from the lesion itself.
Operative data
Ten studies presented data on the extent of resection performed
for FNH in a total of 248 patients.5–8,10–12,14–16 Six studies provided
data on the sizes of the hepatic lesions removed and the anatomi-
cal extent of resection.5,7,8,10,11,15 Major versus minor hepatic resec-
tion was inferred from the data presented, and the techniques
employed are reviewed where presented.
Charny and colleagues8 performed right or left lobectomy in
six patients (33%), trisegmentectomy in two patients (11%),
segmentectomy in three patients (17%) and tumour enucleation
in seven patients (39%). The median size of the resected tumours
was 7.1 cm (range: 2–30 cm). Lesions resected from symptomatic
patients demonstrated a trend towards a larger size compared
with those from asymptomatic individuals (median diameter:
7.3 cm versus 4.4 cm).8
All of the 48 FNH and three hamartoma patients reported in
the multinational series published by Descottes et al. underwent
minor laparoscopic resections.11 The procedures performed
included 14 (27%) left lateral sectionectomies, 12 (24%) non-left
lateral segmentectomies and 25 (49%) non-anatomic resections.
In six (12%) patients, a laparoscopic procedure was converted to
open surgery as a result of significant bleeding (n = 2, 33%), a
tumour location unfavourable to laparoscopic resection (n = 3,
50%) or instrument dysfunction (n = 1, 17%). The median diam-
eter of the resected lesions was larger in the symptomatic group
than in the asymptomatic group [5 cm (range: 2–11 cm) versus
4 cm (range: 1–6 cm)], but the difference was not significant.11
Shen and co-workers7 performed liver resections in 86 patients
with FNH between 1996 and 2006. Hemi-hepatectomy was
carried out in 17 (20%) patients, although most patients under-
went non-anatomic wedge resection of FNH lesions (n = 68,
79%). One (1%) patient had 23 separate foci of FNH throughout
both liver lobes; three foci with diameters of > 2 cm were
enucleated and the remainder treated with electrocautery. The
mean diameter of resected lesions in all patients was 3 cm (range:
0.3–15 cm).7
Bonney and colleagues5 retrospectively examined 52 cases of
FNH, 15 of which had been managed with surgery.
Trisectionectomy was performed in three (20%) patients, lobec-
tomy in three (20%), segmentectomy in one (7%) and non-
anatomic resection in eight (53%). The median size of resected
FNH lesions was 6.1 cm. Across the entire FNH study population,
data derived from preoperative imaging demonstrated a signifi-
cant correlation between increased tumour size and symptoms of
pain (P = 0.006).5
Across the 10 studies reviewed,5–8,10–12,14–16 minor resections of
three or fewer Couinaud segments were performed in 79% (n =
198) of patients. Four (2%) patients did not undergo resection,
but instead submitted to operative biopsy (n = 2) or
radiofrequency ablation (RFA) (n = 2) of FNH lesions. Major
resections of greater than three Couinaud segments were per-
formed in 20% (n = 49) of patients. One patient (0.4%) under-
went a liver transplant.
Outcomes
Five studies included follow-up data for 225 patients with benign
disease including FNH.8,9,12,13,17 Five further studies, involving
143 patients, reported FNH-specific morbidity and mortality
statistics.5–7,10,15
Charny and colleagues8 followed 18 patients resected for FNH
for a median period of 16 months. All symptomatic patients (n =
8) reported resolution of symptoms. No late complications were
reported.
Shen et al.7 reported a morbidity rate of 7% (n = 6) in their
series of FNH resections. All of the reported complications were
sub-phrenic collections with associated pleural effusions. During
the follow-up period (0.5–10 years), no recurrence of symptoms
or deaths were reported.
Bonney and colleagues5 provided follow-up data for 15 patients
for a median of 24 months (range: 6–72 months). Three (20%)
patients sufferedpostoperative complications,comprisingone case
of pneumonia, one sub-hepatic abscess requiring percutaneous
drainage, and one wound infection. One death (7%) during
follow-up was reported in a patient who was found to have con-
comitant HCC in the resection specimen. The cause of death was
not given.Two (13%)patients developed recurrent FNHat, respec-
tively, 24 months and 48 months post-resection. The imaging
method used to assess recurrence was not described. One of these
patients also developed mild recurrent symptoms of pain.5
In the series reported by Petri et al.,15 morbidity was observed in
29% (n = 6) of FNH resections and comprised postoperative
bleeding (n = 2, 10%), postoperative jaundice (n = 2, 10%),
fever of unknown origin (n = 1, 5%) and cerebrovascular accident
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(n = 1, 5%). One death (5%) occurred postoperatively following
liver transplantation and was caused by bleeding with consump-
tive coagulopathy.
Dardenne and co-workers10 provided follow-up data on 13
FNH patients as part of a broader series of individuals undergoing
operative or conservative management of benign liver disease. The
authors reported no 30-day postoperative mortality. One patient
in the operative FNH group died of an unrelated cardiac cause
during the follow-up period (median: 115 months; range:
2–233 months). Instances of morbidity were not observed,
although only severe morbidity requiring invasive treatment was
recorded.
Kamphues and colleagues13 used the European Organization
for Research and Treatment of Cancer (EORTC) Quality of Life
(QLQ) C30 questionnaire to evaluate patient satisfaction with
liver resection for benign disease at a median of 50 months post-
operatively (range: 3–95 months). This study represents the only
objective evidence of patient-derived outcomes in this area.
Patients with FNHmade up 33% (n = 27) of the sample; however,
no subgroup analysis was performed. Results from the group as a
whole demonstrated highly significant improvements in global
health status (P = 0.001), social functioning (P = 0.03) and emo-
tional functioning (P = 0.007) following resection. No significant
impact on physical well-being or cognitive functioning was seen.
Significant improvements were also seen in symptoms of pain
(P = 0.001) and fatigue (P = 0.004). A significant majority of the
patients questioned (n = 78, 96%) stated that they would undergo
resection for benign disease again if offered the choice. A major
flaw of this study13 concerns the heterogeneity of pathological
indications for resection. In addition, the lack of evidence for a
causal link between lesions and symptoms leaves potential for
confounding.
In summary, the rate of morbidity experienced by patients
submitted to resection for FNH was 14% (n = 20). No cases of
mortality following hepatic resection of FNH lesions alone were
reported. One case of 30-day mortality (0.7%) was observed; this
occurred in a patient submitted to liver transplant for FNH.
Discussion
The aims of this review were to examine the indications for con-
servative versus surgical management of FNH in contemporary
hepatobiliary practice and to better elucidate the roles of preop-
erative assessment in ensuring that selected strategies result in
benefit to the FNH population. In fact, much of the debate uncov-
ered stems from the ‘indeterminate lesion’, which frequently
appears as the preoperatively suspicious lesion diagnosed as FNH
on postoperative histology. Indeed, the majority of studies dis-
cussed cite ‘diagnostic uncertainty’ as the principal indicator for
surgery.
Current methods of investigation for the diagnosis and charac-
terization of liver lesions are radiological and principally comprise
US, CT and MRI. The modalities employed in the majority of
patients involved US and CT, and fewer than half of patients
received basic MRI. This is remarkable given the number of
studies showing that MRI has the highest sensitivity in the diag-
nosis of FNH.Current data suggest that a combination of imaging
modalities which includes MRI allows for greater accuracy in
diagnosing FNH, with a sensitivity and specificity for FNH of
> 90%.5,7,19–23 It is therefore imperative that MRI is employed
in situations of diagnostic doubt.
Focal nodular hyperplasia may be definitively non-
histologically diagnosed in circumstances in which specific
characteristic features are present on multiphase CT and contrast-
enhanced MRI. In CT, a lesion exhibiting homogeneous late arte-
rial phase enhancement with a hypodense central scar is
diagnostic of FNH. The FNH enhancement pattern on MRI is
similar to that seen in multiphase CT and the central scar will
demonstrate high signal on T2 weighted images.21 The use of
hepatobiliary MRI contrast agent allows for the definitive descrip-
tion of a hyperintense FNH lesion with low signal in the central
scar. Indeed, the use of gadolinium-based MRI contrast agents
significantly increases the accuracy of diagnosis of FNH, as well
as improving the differentiation of FNH from malignant
lesions.19,22,23 None of the studies considered in this review con-
firmed the use of gadolinium contrast-enhanced MRI in their
preoperative imaging protocols, although they may have done so.
Equally, the purportedly high rates of diagnostic accuracy of con-
trast MRI are not uniformly internally validated through histo-
logical confirmation of the FNH diagnosis.19,22,23
The studies included in this review report a high proportion of
patients undergoing resection of indeterminate hepatic lesions. A
notable historical study performed prior to the inclusion period
of this analysis was published by Belghiti and colleagues in 1993.24
It described 51 patients submitted to resection for presumed
benign lesions, in three (6%) of whommalignancy was proven. In
22 of the 51 patients, the indication for resection was diagnostic
uncertainty.24 The obvious conclusion is that despite the availabil-
ity of better imaging, later observations continue to reflect a
prevalence of suboptimal preoperative imaging and diagnostic
uncertainty. Clearly, it is sensible to offer surgery to patients in
whom it has not been possible to reliably exclude malignancy.
However, the discussed potential of the use of contrast-enhanced
MRI for the accurate diagnosis of FNH would suggest that its
universal use might result in a significant reduction in the
numbers of asymptomatic FNH patients proceeding to unneces-
sary resection.
In patients in whom diagnosis remains uncertain, options
include resection, as discussed and with concomitant mortality
and morbidity, biopsy with histological analysis, and conservative
management with repeated imaging. Biopsy can be achieved in
various ways; there is some dichotomy between image-guided
percutaneous and laparoscopic techniques. The aim of lesional
biopsy is to achieve a definitive diagnosis and hence to avoid
surgery for benign lesions. Biopsy of these indeterminate lesions is
controversial because of two factors. The first is further diagnostic
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inaccuracy. Some of the series reviewed herein show evidence of
sampling error with poor sensitivity and specificity seen in the
context of retrospective analyses.5,11 The difficulty of distinguish-
ing large FNH lesions from well-differentiated or fibrolamellar
HCC on biopsy histology is also well reported.25 A second issue
concerns the risk for needle track seeding of tumour cells from
what may be a potentially operable malignant lesion.
Laparoscopic biopsy with intraoperative US guidance is an
alternative to the percutaneous route and is potentially advanta-
geous in terms of both procuring representative tissue and reduc-
ing the risk for tumour seeding. These perceived advantages have
yet to be demonstrated in the literature. However, quantitative
data regarding the observed risk for tumour seeding following
percutaneous biopsy of malignant hepatic lesions are available in
the literature and the risk is small. Azoulay and colleagues26
reported an incidence of < 2%, which suggests this issue to be of
minor importance. In addition, it should be remembered that the
majority of lesions biopsied will prove to be benign and hence
seeding is not a concern.
There are several published algorithms which advise that where
diagnostic doubt exists after imaging, percutaneous biopsy should
be avoided in operable disease.5,8,9,18,27 In most cases, patients with
a suspicious liver lesion are offered liver resection. If indeed future
studies suggest biopsy should be performed laparoscopically,
some would argue that, given the very low rates of morbidity
recorded, resection could preferentially be performed to give the
added benefit of a definitive outcome. However, in patients in
whom individual factors favouring conservative approaches to
management pertain (including patient choice), a robust biopsy
protocol properly performed and repeat follow-up imaging both
represent safe practice.
Knowledge regarding the prevalence and natural history of
FNH is evolving as a result of the expanding use of modern,
high-resolution, cross-sectional imaging. Prospective cohort
studies suggest that around a quarter of FNH detected incidentally
will be symptomatic and that the majority will remain stable in
terms of size. In 2001, D’Halluin and colleagues reported out-
comes in 44 cases of FNH followed prospectively in France over a
median of 45 months.28 Ten (23%) patients were symptomatic at
the beginning of the study period, but by the end all symptoms
had resolved.28 No other complications of conservative manage-
ment, including bleeding or rupture, were reported. In addition,
the findings of a recent cohort study suggest that the majority of
conservatively managed FNH lesions remain stable after diagnosis
and a proportion regress over time.29
In patients with symptomatic FNH, several studies have
reported that surgical resection is an effective treatment that pro-
vides for favourable levels of patient satisfaction and a low inci-
dence of symptom recurrence.6,7,12 However, the two studies5,10
reviewed herein that assessed medium- and longterm outcomes of
conservative FNH management reported that 80% of 25 sympto-
matic patients experienced the resolution of their symptoms with
conservative management.
Hepatic resection for benign pathology is associated with
acceptably low incidences of morbidity and mortality. In all of the
14 case series concerning surgical management of benign liver
disease discussed in the present paper, the only case of
perioperative mortality occurred following liver transplantation.
The levels of morbidity observed are also acceptable and compare
favourably with those seen after resections for malignant disease.
This may in part reflect the fact that FNH is more commonly seen
in a younger population than is malignant disease and that major
resections are less likely to be necessary.17,18
The numbers of liver resections performed worldwide have
increased dramatically in the recent past. The reasons for these
increases relate tomany factors, including the expansion of hepatic
resection for colorectal liver metastases and the introduction of
low-morbidity laparoscopic resection techniques.As a result,many
centreswill feel comfortable in performing large numbers ofminor
resections for benign disease.30 There is no direct evidence that the
development and expansion of laparoscopic liver resection have
increased rates of resection for benigndisease.However, an analysis
of published patterns of resection for benign liver lesions con-
ducted by Toro and colleagues suggests a possible increase in the
rate of FNH resection associated with the laparoscopic era.31 It
might be argued that the availability of well-tolerated, low-risk
procedures has reduced the drive to deliver reference-standard
imaging and reduced resection rates.
The existing literature relating specifically to the management
of FNH is incomplete. In the last 10 years, only three case series,
involving a total of 109 patients, focusing on the surgical manage-
ment of FNH have been published.5–7 Shen and colleagues have
published the largest series to date; their information regarding
preoperative imaging and post-resection outcome was compiled
retrospectively using postoperative histology to identify FNH
patients.7 Indeed, the majority of studies including data relevant
to the management of FNH retrospectively report outcomes from
single-centre ‘benign disease’ case series. Thus Level III evidence
from small subgroup analysis is the rule. There is currently no
Level I or II evidence to assist clinical decision making in the
management of FNH.
The aim of this systematic reviewwas to assess the indications for
and outcomes of the operative management of FNH. Potential
modalities not assessed include radiological embolization and RFA.
The successful management of FNH employing these techniques
either as primary treatment32–35 or as adjunctive to surgical resec-
tion36 has been reported. There are currently no published accounts
of randomized controlled trials (RCTs) comparing the outcomes of
embolization or RFA with those of either open resection or con-
servative management. The major limitation of local embolization
or ablation techniques is the lack of post-procedural histology. This
is particularly relevant as the accuracy of preoperative imaging and
biopsy-derived diagnosis of FNH is fallible. Embolization, RFA and
any other techniques employing similar principles would neces-
sarily be limited to symptomatic patients in whom pre-procedural
investigations allow a definitive FNH diagnosis.
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Conclusions
Patients who present with potential FNH lesions should be
imaged with multiphase CT and contrast-enhanced MRI. In
patients in whom contrast-enhanced MRI is not employed, diag-
nostic accuracy is inferior and the rate of unnecessary resection
may be high. Further study of this modality and its correlation
to reference-standard histological FNH confirmation would
strengthen this recommendation. Patients in whom state-of-the-
art imaging studies have been inconclusive should be offered a
range of options. They must be made fully aware of the potential
for malignancy, but assured that a benign diagnosis is more likely.
Principles of informed consent and patient choice should be exer-
cised when discussing options of resection, percutaneous or
laparoscopic biopsy, repeat imaging to observe for lesional change
and conservative management.
Patients presenting with asymptomatic definitive FNH can be
safely managed conservatively. In symptomatic patients surgical
resection is a safe and effective treatment. However, reports of the
spontaneous improvement or resolution of FNH-related symp-
toms with conservative management suggest this also remains a
viable option (Fig. 2).
The evidence base for the management of FNH is weak. For
symptomatic patients, a multicentre RCT comparing operative
with conservative management strategies would provide the first
Level I evidence for the effect of surgery on symptoms presumed
to be caused by the FNH tumour. However, issues of diagnostic
uncertainty may cause accrual problems for such a study. In addi-
tion, the optimal management of symptomatic FNH is subordi-
nate to the issue of diagnostic uncertainty.
In recent years the hepatobiliary surgical community appears to
have responded to the oncological risk for diagnostic uncertainty
by performing an increasing number of safe hepatic resections in
which the final histological diagnosis confirms the presence of
FNH. By limiting diagnostic uncertainty through the use of state-
of-the-art imaging, the individual and societal burdens imposed
by the subjection of patients to surgical treatment for an entirely
benign entity can be minimized. Therefore, the clear message
of this review is that diagnostic uncertainty remains the prin-
cipal valid indication for FNH resection, but only in patients in
whom contrast-enhanced MRI forms part of the preoperative
assessment.
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